SureTrader SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Bioheart, Inc. (BHRT)

Add BHRT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 9/1/2015 5:43:38 PM - Followers: 168 - Board type: Free - Posts Today: 10


Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


MyoCell SDF-1 



Bioheart’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell.

The MyoCath is a disposable needle injection catheter used for the delivery of biologic solutions to a targeted treatment site within the myocardium, the inner wall of the heart. 

Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells.  Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy.  


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
BHRT - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
BHRT News: Proxy Statement - Other Information (preliminary) (pre 14c) 08/26/2015 05:12:06 PM
BHRT News: Quarterly Report (10-q) 08/03/2015 12:05:19 PM
BHRT News: Statement of Ownership (sc 13g) 07/27/2015 10:48:14 AM
BHRT News: Current Report Filing (8-k) 06/22/2015 12:01:10 PM
BHRT News: Statement of Changes in Beneficial Ownership (4) 05/26/2015 04:31:50 PM
#16301   My main concern is how liquid the stock EquityElite 09/01/15 05:43:38 PM
#16300   .0032, ANOTHER ALL TIME CLOSING LOW AGAIN !! Captain Kirk 09/01/15 04:31:43 PM
#16297   I know they will not have any problems Rosym 09/01/15 01:49:37 PM
#16296   It takes FINRA and SEC approval - it's Captain Kirk 09/01/15 01:45:01 PM
#16295   They have the Board Approval of the Reverse Rosym 09/01/15 01:36:53 PM
#16294   Re-positioning with an RS and name change has gypsydoc 09/01/15 01:35:44 PM
#16293   Bid ALL back in .002's FELL OFF CLIFF AGAIN Captain Kirk 09/01/15 12:40:12 PM
#16292   Did they say the reason why they are Rosym 09/01/15 08:00:01 AM
#16291   RED, NEW ALL TIME CLOSING LOW @ .0035 !! Captain Kirk 08/31/15 06:07:16 PM
#16290   I guarantee you that the day after the Paulness 08/31/15 04:16:45 PM
#16289   It's going to be interesting that's for sure. EquityElite 08/31/15 03:41:07 PM
#16288   1000 to 1 rs is ridiculous that would Paulness 08/31/15 03:28:24 PM
#16287 JWMN 08/31/15 02:13:58 PM
#16286   Quote, "I was thinking if they would still Captain Kirk 08/31/15 12:00:04 PM
#16285   I was thinking if they would still be EquityElite 08/31/15 11:47:08 AM
#16284   Bid, ALL .002's again- it looks like FREE Captain Kirk 08/31/15 11:38:04 AM
#16283   I would assume the "notes" (aka convertible debt) Captain Kirk 08/31/15 10:51:24 AM
#16282   If you buy before a RS can you EquityElite 08/31/15 10:47:47 AM
#16281   Do you know if any of the note EquityElite 08/31/15 08:45:44 AM
#16280   Quote, "Where did you find this quote? I Captain Kirk 08/30/15 11:49:26 AM
#16279   Where did you find this quote? I Feedthemonster 08/30/15 03:21:56 AM
#16278   "PLEASE NOTE THAT THE REVERSE STOCK SPLIT WILL EquityElite 08/28/15 07:15:39 PM
#16277   Great isn't it. They are going to run this photo4u 08/28/15 05:28:29 PM
#16275   BMAK gonna try and paint it, in the Captain Kirk 08/28/15 04:07:58 PM
#16274   Ha, so many people getting shook out photo4u 08/28/15 04:06:23 PM
#16273   Here comes the bounce BOING photo4u 08/28/15 12:14:50 PM
#16272   Market cap BARELY holding $2 MILLION bucks Captain Kirk 08/28/15 12:11:19 PM
#16271   What's the MC at .003? EquityElite 08/28/15 11:53:17 AM
#16270   Nice early morning shake, I expect a big photo4u 08/28/15 10:13:51 AM
#16269   Bid is paper THIN to low .002's again Captain Kirk 08/28/15 10:07:38 AM
#16268   Wow this recovered today nicely. Nice close to EquityElite 08/27/15 04:23:05 PM
#16267   Volume before price.... That was some serious volume photo4u 08/27/15 04:22:31 PM
#16266   Bid is still micro THIN to the .002's Captain Kirk 08/27/15 03:30:48 PM
#16265   No, something around 800+ is outstanding Lutfiyah holdings 08/27/15 03:16:46 PM
#16264   This is going to close hod photo4u 08/27/15 02:43:48 PM
#16263   Yeah, me photo4u 08/27/15 02:28:03 PM
#16262   Wow looks like somebody buyin! EquityElite 08/27/15 02:26:27 PM
#16261   any specific reason why you think its beneficial saratg 08/27/15 01:04:12 PM
#16260   Spread went like 40% LOL !!!! No freaking way????? Captain Kirk 08/27/15 12:30:35 PM
#16259   Go time photo4u 08/27/15 12:09:11 PM
#16258   Haha, $$$$$ photo4u 08/27/15 11:57:31 AM
#16257   4.7 mil buy at .0032 photo4u 08/27/15 11:34:41 AM
#16256   Weeeee So many cheapies photo4u 08/27/15 11:10:17 AM
#16255   0.0028 / 0.0031 (20000 x 385000) WOW !! Captain Kirk 08/27/15 11:07:40 AM
#16254   Still waiting to get in this. Will scoobydooby 08/27/15 10:56:27 AM
#16253   Might be $1.50 by the time they split Captain Kirk 08/27/15 10:30:04 AM
#16252   Somebody sold me a whopping 40 shares at .0026 photo4u 08/27/15 10:26:48 AM
#16251   I still waiting for my bid to fill photo4u 08/27/15 10:22:37 AM
#16250   What are they waiting for? photo4u 08/27/15 10:21:43 AM
#16249   Looks like CONVERTIBLE DEBT BOYS are gonna "convert" Captain Kirk 08/27/15 10:14:00 AM